MARKET

PAVM

PAVM

PAVmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.20
-0.19
-2.02%
After Hours: 9.20 0 0.00% 19:26 09/24 EDT
OPEN
9.22
PREV CLOSE
9.39
HIGH
9.60
LOW
9.05
VOLUME
1.92M
TURNOVER
--
52 WEEK HIGH
9.70
52 WEEK LOW
1.630
MARKET CAP
779.86M
P/E (TTM)
-16.7303
1D
5D
1M
3M
1Y
5Y
Why PAVmed Shares Are Trading Higher Today
PAVmed Inc (NASDAQ: PAVM) is trading higher Thursday after the company announced its majority-owned subsidiary, Lucid Diagnostics, filed a registration statement for a proposed initial public offering.
Benzinga · 3d ago
PAVmed's Subsidiary, Lucid Diagnostics Files For $58M IPO
Lucid Diagnostic, a maker of diagnostic tests for esophageal precancer and cancer, filed to raise up to $58 million in an IPO.
Benzinga · 3d ago
ONTX, RWLK and MRIN among mid-day movers
Gainers: TransCode Therapeutics (NASDAQ:RNAZ) +79%. MEDIROM (NASDAQ:MRM) +77%. ReWalk Robotics Ltd. (NASDAQ:RWLK) +38%. TScan Therapeutics (NASDAQ:TCRX) +29%. AeroCentury (NYSE:ACY) +20%. Transcontinental Realty Investors (NYSE:TCI) +19%. Neonode (NASDAQ:N...
Seekingalpha · 3d ago
PAVmed Unit Lucid Diagnostics Files For IPO; Shares Rise
MT Newswires · 3d ago
Top Midday Gainers
MT Newswires · 3d ago
BRIEF-PAVmed Says Subsidiary Lucid Diagnostics Filed Registration Statement For Proposed Initial Public Offering
reuters.com · 3d ago
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement For Proposed Initial Public Offering
PAVmed Inc. (NASDAQ:PAVM, PAVMZ)))) ("PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology company, and its majority-owned subsidiary, Lucid Diagnostics Inc.
Benzinga · 3d ago
DPW, JOBY and CEI among pre market gainers
MEDIROM Healthcare Technologies (NASDAQ:MRM) +77% on deal for ZACC Kabushiki Kaisha Digital Brands (NASDAQ:DBGI) +27%. TransCode Therapeutics (NASDAQ:RNAZ) +15% announces publication in cancer nanotechnology of preclinical data supporting therapeutic poten...
Seekingalpha · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PAVM. Analyze the recent business situations of PAVmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PAVM stock price target is 8.75 with a high estimate of 10.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 21.12M
% Owned: 24.92%
Shares Outstanding: 84.77M
TypeInstitutionsShares
Increased
34
3.54M
New
29
1.92M
Decreased
22
1.12M
Sold Out
19
1.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.19%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chairman/Chief Executive Officer/Director
Lishan Aklog
President/Chief Financial Officer/Secretary
Dennis Mcgrath
Vice Chairman/Independent Director
Michael Glennon
Other
Brian DeGuzman
Director
Tim Baxter
Director
Debra White
Independent Director
James Cox
Independent Director
Ronald Sparks
Independent Director
David Weild
No Data
About PAVM
PAVmed Inc. is a multi-product, commercial-stage technology medical device company. The Company has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.

Webull offers kinds of PAVmed Inc stock information, including NASDAQ:PAVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PAVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PAVM stock methods without spending real money on the virtual paper trading platform.